Albumin is extensively and most commonly used as blood volumizer. In particular, the human serum albumin is used in a wide spectrum of conditions such as shocks, burns, liver conditions, rare diseases, and a host of blood loss trauma and surgeries.
Albumin is extensively and most commonly used as blood volumizer. In particular, the human serum albumin (HAS) is used in a wide spectrum of conditions such as shocks, burns, liver conditions, rare diseases, and a host of blood loss trauma and surgeries. The substantially rising application of this protein as multifunctional excipients opened altogether a new avenue in the pharmaceutical and healthcare sectors world over.
Albumin emerged as copiously promising as excipients for various biotechnology products. It has also gathered immense traction in the industries by serving as a versatile drug carrier system for achieving novel therapeutic ends. Riding on the back of these applications, the prospects for albumin (as excipient) market is immense. A recent report by Transparency Market Research valued the global market at US$750 Mn in 2017 and projects the opportunities to reach a worth of US$1200 Mn by the end of 2026.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3984
Novel Drug Development Initiatives to leverage Potential of Recombinant Human Serum Albumin
Advances in drug formulation and drug delivery have centered on a few factors of which the objective of researchers in reducing the immunogenicity and enhancing the efficacy of the drugs is perhaps the most vital. The demand of recombinant proteins as a preferred choice in drug formulation across the globe stemmed from this trend.
Against the above backdrop, the use of recombinant human serum albumin, an advanced form of HSA, has risen in significance in recent times in the pharmaceutical industries. The demand for this product type in the global albumin (as excipient) market is projected to rise at a staggering pace from 2018 to 2026. This can be primarily attributed to several attractive characteristics of recombinant human serum albumin such as being least immunogenic in patient’s body, thereby helping in stabilizing the drug formulations against surface adsorption, aggregation, and oxidation.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=3984
The rising number of regulatory approvals recombinant albumin fusion protein for treating rare diseases in several countries is creating new revenue streams for market players. CSL Behring, a U.S.-based biopharmaceutical company, announced in August 2018 that novel recombinant albumin fusion protein, approved for treating hemophilia B, is now available in a different vial size. The vial size is critical for reducing the reconstitution time for multiple vials and thus help in better management of the disease.
Buy Albumin (as Excipient) Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=3984<ype=S
Major players in the global albumin (as excipient) market are Albumedix A/S (Novozyme A/S), Albumin Therapeutics, LLC, Biotest AG, CSL Behring LLC, Grifols International, S.A., HiMedia Laboratories Pvt. Ltd., InVitria, Medxbio Pte Ltd., Octapharma AG, RayBiotech, Inc., SeraCare Life Sciences, and Sigma-Aldrich Co. (Merck KGaA). The companies are focusing on partnering with leading pharmaceutical companies to boost the research and development activities in order to develop technologically advanced albumin products.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”
Contact
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/
